| Regimen . | First-month costs (JPY) . | Total (n = 907) No. (%) . | <75 years (n = 674) No. (%) . | ≥75 years (n = 233) No. (%) . |
|---|---|---|---|---|
| Pembrolizumab | 612 851 | 330 (36.4) | 198 (29.4) | 132 (56.7) |
| Nivolumab | 785 153 | 202 (22.3) | 158 (2.4) | 44 (18.9) |
| CDDP +5-FU + Pembrolizumab | 634 504 | 153 (16.9) | 139 (20.6) | 14 (6.0) |
| CBDCA +5-FU + Pembrolizumab | 630 692 | 125 (13.8) | 95 (14.1) | 30 (12.9) |
| PTX + CBDCA + Cetuximab | 849 241 | 53 (5.8) | 48 (7.1) | 5 (2.1) |
| Clinical trial | – | 29 (3.2) | 24 (3.6) | 5 (2.1) |
| CDDP +5-FU + Cetuximaba | 836 807 | 8 (0.9) | 6 (0.9) | 2 (0.9) |
| CBDCA +5-FU + Cetuximaba | 832 995 | 7 (0.8) | 6 (0.9) | 1 (0.4) |
| Regimen . | First-month costs (JPY) . | Total (n = 907) No. (%) . | <75 years (n = 674) No. (%) . | ≥75 years (n = 233) No. (%) . |
|---|---|---|---|---|
| Pembrolizumab | 612 851 | 330 (36.4) | 198 (29.4) | 132 (56.7) |
| Nivolumab | 785 153 | 202 (22.3) | 158 (2.4) | 44 (18.9) |
| CDDP +5-FU + Pembrolizumab | 634 504 | 153 (16.9) | 139 (20.6) | 14 (6.0) |
| CBDCA +5-FU + Pembrolizumab | 630 692 | 125 (13.8) | 95 (14.1) | 30 (12.9) |
| PTX + CBDCA + Cetuximab | 849 241 | 53 (5.8) | 48 (7.1) | 5 (2.1) |
| Clinical trial | – | 29 (3.2) | 24 (3.6) | 5 (2.1) |
| CDDP +5-FU + Cetuximaba | 836 807 | 8 (0.9) | 6 (0.9) | 2 (0.9) |
| CBDCA +5-FU + Cetuximaba | 832 995 | 7 (0.8) | 6 (0.9) | 1 (0.4) |
CDDP, cisplatin; CBDCA, carboplatin; 5-FU, 5-fluorouracil; ICI, immune checkpoint inhibitor; PTX, paclitaxel.
aEXTREME trial.
| Regimen . | First-month costs (JPY) . | Total (n = 907) No. (%) . | <75 years (n = 674) No. (%) . | ≥75 years (n = 233) No. (%) . |
|---|---|---|---|---|
| Pembrolizumab | 612 851 | 330 (36.4) | 198 (29.4) | 132 (56.7) |
| Nivolumab | 785 153 | 202 (22.3) | 158 (2.4) | 44 (18.9) |
| CDDP +5-FU + Pembrolizumab | 634 504 | 153 (16.9) | 139 (20.6) | 14 (6.0) |
| CBDCA +5-FU + Pembrolizumab | 630 692 | 125 (13.8) | 95 (14.1) | 30 (12.9) |
| PTX + CBDCA + Cetuximab | 849 241 | 53 (5.8) | 48 (7.1) | 5 (2.1) |
| Clinical trial | – | 29 (3.2) | 24 (3.6) | 5 (2.1) |
| CDDP +5-FU + Cetuximaba | 836 807 | 8 (0.9) | 6 (0.9) | 2 (0.9) |
| CBDCA +5-FU + Cetuximaba | 832 995 | 7 (0.8) | 6 (0.9) | 1 (0.4) |
| Regimen . | First-month costs (JPY) . | Total (n = 907) No. (%) . | <75 years (n = 674) No. (%) . | ≥75 years (n = 233) No. (%) . |
|---|---|---|---|---|
| Pembrolizumab | 612 851 | 330 (36.4) | 198 (29.4) | 132 (56.7) |
| Nivolumab | 785 153 | 202 (22.3) | 158 (2.4) | 44 (18.9) |
| CDDP +5-FU + Pembrolizumab | 634 504 | 153 (16.9) | 139 (20.6) | 14 (6.0) |
| CBDCA +5-FU + Pembrolizumab | 630 692 | 125 (13.8) | 95 (14.1) | 30 (12.9) |
| PTX + CBDCA + Cetuximab | 849 241 | 53 (5.8) | 48 (7.1) | 5 (2.1) |
| Clinical trial | – | 29 (3.2) | 24 (3.6) | 5 (2.1) |
| CDDP +5-FU + Cetuximaba | 836 807 | 8 (0.9) | 6 (0.9) | 2 (0.9) |
| CBDCA +5-FU + Cetuximaba | 832 995 | 7 (0.8) | 6 (0.9) | 1 (0.4) |
CDDP, cisplatin; CBDCA, carboplatin; 5-FU, 5-fluorouracil; ICI, immune checkpoint inhibitor; PTX, paclitaxel.
aEXTREME trial.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
